Bartoletti M, et al. - Researchers here aimed to assess if treatment with a tigecycline-based antimicrobial regimen for intra–abdominal infection (IAI) could be associated with lower rates of subsequent carbapenem-resistant Enterobacteriaceae (CRE) colonisation or Clostridium difficile infection (CDI) compared with a meropenem-based regimen. They found a 10-fold lower incidence of CDI in association with tigecycline-based regimens for IAI compared with meropenem-based regimens. However, the two regimes were not different in the incidence of CRE colonisation.